Market Research Reports Global Implantable Neurostimulators Market Report | Page 2

Available Exclusive Sample Copy of this Report @
https://www.businessindustryreports.com/sample-request/102611 .
The Global Implantable Neurostimulators Market is segmented in the basis of Type, Appli cation and
Region. Based on the Type, the Global Implantable Neurostimulators Market is classified into Deep
Brain Stimulators, Spinal Cord Stimulators, Vagal Nerve Stimulators, Sacral Nerve Stimulators, and
others. On the b basis of Application, the Global Implantable Neurostimulators Market is sub-
segmented into Parkinson’s disease, Epilepsy, Pain, and Others.
Industry Updates:
1 NeuroSigma (April 23, 2019) – NeuroSigma Announces FDA Clearance of Monarch eTNS System as
First Non-Drug Treatment for Pediatric ADHD – NeuroSigma, Inc., a Los Angeles-based bioelectronics
company focused on commercializing Trigeminal Nerve Stimulation (TNS) technology for treating
neurological and neuropsychiatric disorders today announced that its Monarch eTNS System
(Monarch) received FDA clearance as a non-drug treatment for attention deficit hyperactivity
disorder (ADHD).
The prescription-only Monarch device is indicated for treatment of pediatric ADHD as a
monotherapy in patients ages 7 through 12 years old who are not currently taking prescription
ADHD medications. The device is intended to be used in the home under the supervision of a
caregiver during periods of sleep.
"We are extremely pleased by FDA's clearance of the Monarch as a monotherapy for pediatric
ADHD. We want to thank the FDA team for their efforts during the review process to bring it to a
timely and successful completion," said Leon Ekchian, Ph.D., President & CEO of NeuroSigma. "We
also want to applaud the efforts of the clinical team at UCLA. We look forward to building a
commercial organization in the U.S. to offer children, their parents and their physicians a compelling,
low-risk, non-drug alternative to current medication treatment options for ADHD," added Ekchian.
2 NeuroPace (February 12, 2019) – NeuroPace Announces New Category I CPT Code from AMA for
Electrocorticography from an Implanted Brain Neurostimulator – NeuroPace, Inc., a Silicon Valley-
based medical technology company, today announced that the American Medical Association (AMA)
has issued a new Category I Current Procedural Terminology (CPT®) code for electrocorticography
from an implanted brain neurostimulator. The new code is applicable to services that physicians
perform with the company’s RNS® System, a first-of-its-kind technology for the treatment of
patients with refractory epilepsy.
Beginning January 1, 2019, providers are able to report the new CPT code for the review and
interpretation of electrocorticograms (measurements of brain activity) captured and stored by the
RNS System. CPT codes are widely recognized by public and private health insurance payers in the
United States to describe healthcare services and procedures to facilitate reimbursement. The CPT
code application was submitted by the American Academy of Neurology, American Clinical
Neurophysiology Society, and the National Association of Epilepsy Centers.
Top Leading Key Manufacturers are: Medtronic, Boston Scientific, St. Jude Medical, Cyberonics,
NeuroPace, Synapse Biomedical, NeuroSigma, EnteroMedics, ElectroCore Medical, Inspire Medical,
NEUROS, SPR, IMTHERA, NEVRO and others. New product launches and continuous technological
innovations are the key strategies adopted by the major players.
With the presence of a large pool of participants, the Global Implantable Neurostimulators Market is
displaying a highly competitive business landscape, finds a new research report by Business Industry